The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment
Open accessAbstract
The aim of the present study was to investigate the effect of long-term infliximab treatment on various autoantibodies in patients with rheumatoid arthritis. Serum samples from 30 consecutive patients, who were prospectively followed during infliximab and methotrexate therapy for refractory rheumatoid arthritis, were tested at baseline and after 30, 54 and 78 weeks. At these points, median values of the Disease Activity Score were 6.38 (interquartile range 5.30-6.75), 3.69 (2.67-4.62), 2.9 (2.39-4.65) and 3.71 (2.62-5.06), respectively. Various autoantibodies were assessed by standard indirect immunofluorescence and/or ELISA. Initially, 50% of patients were positive for antinuclear antibodies, and this figure increased to 80% after 78 weeks (P = 0.029). A less marked, similar increase was found for IgG and IgM anticardiolipin antibody titre, whereas the frequency of anti-double-stranded DNA antibodies (by ELISA) exhibited a transient rise (up to 16.7%) at 54 weeks and dropped to 0% at 78 weeks. Antibodies to proteinase-3 and myeloperoxidase were not detected. The proportion of patients who were positive for rheumatoid factor (RF) was similar at baseline and at 78 weeks (87% and 80%, respectively). However, the median RF titre exhibited a progressive reduction from 128 IU/ml (interquartile range 47-290 IU/ml) to 53 IU/ml (18-106 IU/ml). Anti-cyclic citrullinated peptide (CCP) antibodies were found in 83% of patients before therapy; anti-CCP antibody titre significantly decreased at 30 weeks but returned to baseline thereafter. In conclusion, the presence of anti-double-stranded DNA antibodies is a transient phenomenon, despite a stable increase in antinuclear and anticardiolipin antibodies. Also, the evolution of RF titres and that of anti-CCP antibody titres differed during long-term infliximab therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vermeire, S., Noman, M., Van Assche, G., Baert, F., Van Steen, K., Esters, N., Joossens, S., Bossuyt, X., & Rutgeerts, P. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00701-7 · Cited by 327
Cited by
Avouac, J., Gossec, L., & Dougados, M. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.051391 · Cited by 486
Immunity to Citrullinated Proteins in Rheumatoid Arthritis
Klareskog, L., Rönnelid, J., Lundberg, K., Padyukov, L., & Alfredsson, L. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090244 · Cited by 463
Rheumatoid Factors: Clinical Applications
Ingegnoli, F., Castelli, R., & Gualtierotti, R. (2013) · Disease Markers · doi:10.1155/2013/726598 · Cited by 351
Kapetanovic, M. C., Saxne, T., Sjöholm, A., Truedsson, L., Jönsson, G., & Geborek, P. (2006) · Rheumatology · doi:10.1093/rheumatology/kei193 · Cited by 319
Anti–citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis
Aggarwal, R., Liao, K., Nair, R., Ringold, S., & Costenbander, K. H. (2009) · Arthritis Care & Research · doi:10.1002/art.24827 · Cited by 253
Metadata
- Authors
- Bobbio-Pallavicini, F., Alpini, C., Caporali, R., Avalle, S., Bugatti, S., & Montecucco, C.
- Venue
- Arthritis Res Ther
- Published
- 2004-04-26
- Volume
- 6
- Issue
- 3
- Pages
- R264-72
- ISSN
- 1478-6354 (ISSN-L)
- OpenAlex
- W2096153127
- Cited by
- 163
- References
- 1
- FWCI
- 10.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.